Most Popular
1. Banking Crisis is Stocks Bull Market Buying Opportunity - Nadeem_Walayat
2.The Crypto Signal for the Precious Metals Market - P_Radomski_CFA
3. One Possible Outcome to a New World Order - Raymond_Matison
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
5. Apple AAPL Stock Trend and Earnings Analysis - Nadeem_Walayat
6.AI, Stocks, and Gold Stocks – Connected After All - P_Radomski_CFA
7.Stock Market CHEAT SHEET - - Nadeem_Walayat
8.US Debt Ceiling Crisis Smoke and Mirrors Circus - Nadeem_Walayat
9.Silver Price May Explode - Avi_Gilburt
10.More US Banks Could Collapse -- A Lot More- EWI
Last 7 days
Stock Market Volatility (VIX) - 25th Mar 24
Stock Market Investor Sentiment - 25th Mar 24
The Federal Reserve Didn't Do Anything But It Had Plenty to Say - 25th Mar 24
Stock Market Breadth - 24th Mar 24
Stock Market Margin Debt Indicator - 24th Mar 24
It’s Easy to Scream Stocks Bubble! - 24th Mar 24
Stocks: What to Make of All This Insider Selling- 24th Mar 24
Money Supply Continues To Fall, Economy Worsens – Investors Don’t Care - 24th Mar 24
Get an Edge in the Crypto Market with Order Flow - 24th Mar 24
US Presidential Election Cycle and Recessions - 18th Mar 24
US Recession Already Happened in 2022! - 18th Mar 24
AI can now remember everything you say - 18th Mar 24
Bitcoin Crypto Mania 2024 - MicroStrategy MSTR Blow off Top! - 14th Mar 24
Bitcoin Gravy Train Trend Forecast 2024 - 11th Mar 24
Gold and the Long-Term Inflation Cycle - 11th Mar 24
Fed’s Next Intertest Rate Move might not align with popular consensus - 11th Mar 24
Two Reasons The Fed Manipulates Interest Rates - 11th Mar 24
US Dollar Trend 2024 - 9th Mar 2024
The Bond Trade and Interest Rates - 9th Mar 2024
Investors Don’t Believe the Gold Rally, Still Prefer General Stocks - 9th Mar 2024
Paper Gold Vs. Real Gold: It's Important to Know the Difference - 9th Mar 2024
Stocks: What This "Record Extreme" Indicator May Be Signaling - 9th Mar 2024
My 3 Favorite Trade Setups - Elliott Wave Course - 9th Mar 2024
Bitcoin Crypto Bubble Mania! - 4th Mar 2024
US Interest Rates - When WIll the Fed Pivot - 1st Mar 2024
S&P Stock Market Real Earnings Yield - 29th Feb 2024
US Unemployment is a Fake Statistic - 29th Feb 2024
U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - 29th Feb 2024
What a Breakdown in Silver Mining Stocks! What an Opportunity! - 29th Feb 2024
Why AI will Soon become SA - Synthetic Intelligence - The Machine Learning Megatrend - 29th Feb 2024
Keep Calm and Carry on Buying Quantum AI Tech Stocks - 19th Feb 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Four Telltale Signs of a Bioscience "Blockbuster" Biotech Stock in the Making

Companies / BioTech May 23, 2014 - 02:13 PM GMT

By: Money_Morning

Companies

Ernie Tremblay writes: The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.


They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."

And this is how you find them...

Take These Steps to Spot Your Next Major Winner

For a drug to be chosen for one of these quick approval programs, it has to meet two criteria:

  • It has to treat a serious condition."Serious" means the condition interferes with the patient's normal activities on a long-term basis, or is likely to get worse if left on its own, or is lethal. This drug must be intended to save lives or appreciably improve quality of life.In other words, it must have a ready-made market awaiting its arrival.
  • It has to fill an unmet medical need.This means there is no other approved, available therapy that adequately treats the condition. In other words, this new drug will have a monopoly in the market place.

So when choosing a biotech stock for investment, here are your first steps:

  1. Go to the company's website and locate the link to its pipeline (drugs in development).
  2. Locate its leading new drug candidate - often the page will provide a chart showing which drug is furthest along in development.
  3. Click on whatever link takes you to more details about the drug.
  4. Scan the info on the page for one of these phrases: Fast Track designation; Breakthrough Therapy designation; Accelerated Approval; Priority Review.

If you find any of those four phrases, you've hit pay dirt. 

Now, here's what they mean:

Blockbuster Sign No. 1

Fast Track Designation

A Fast Track designation facilitates the development and expedites the review of drugs that treat serious conditions and fill an unmet medical need. It gives drug developers the opportunity to meet more frequently with the FDA as their product moves through the regulatory gauntlet and allows them to receive a "rolling review" of portions of their marketing application as the process moves forward, rather than submitting everything at the end.

Blockbuster Sign No. 2

Breakthrough Therapy

A Breakthrough Therapy designation accelerates the development and review of drugs that are intended for serious or life-threatening conditions and demonstrate substantial improvement over available therapies for at least one clinically significant endpoint. This designation offers all of the features of the fast track program and includes even more intensive FDA guidance on development.

Blockbuster Sign No. 3

Accelerated Approval

This program speeds up the approval of promising therapies that treat serious or life-threatening conditions and provide a significant benefit over available therapies. This designation allows developers to use "surrogate endpoints," if appropriate, in their research. A surrogateendpoint is a laboratory measure or physical sign that can reasonablysubstitute for a clinically meaningful endpoint to predict positive outcomes.

For example, improved cholesterol levels have been used in place of actual long-term survival data in assessing drugs that treat atherosclerosis. That's a very helpful shortcut in developing drugs for diseases that take a long time to run their course.

However, the FDA may require a manufacturer to continue testing these drugs even after they reach the market, in order to get a real read on long-term benefit. And if the ongoing clinical trials don't confirm the benefits predicted by the surrogate endpoints, the FDA can withdraw its approval.   

Drugs that receive either a Fast Track or a Breakthrough Therapy designation may also receive an Accelerated Approval designation.

Blockbuster Sign No. 4

Priority Review

A Priority Review designation shortens the review goal date to 6 months from the standard of a 10-month waiting period. Fast Track, Breakthrough Therapy, and Accelerated Approval drugs are all eligible for Priority Review designation.

None of these designations guarantee final FDA approval, of course. The clinical trial data still needs to show safety and effectiveness. But because these programs get the agency more intimately involved in the drug development process, there is less likelihood of last-minute snafus, such as a determination that critical data is missing from the NDA (new drug application) when it's finally submitted for review.

And they DO give a clear signal that the new drug is question an important one - and is far more likely to generate that $1 billion in annual sales that is the hallmark of "blockbuster" status.

Source : http://moneymorning.com/2014/05/23/t...

Money Morning/The Money Map Report

©2014 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in